cd40 polyclonal primary antibody  (R&D Systems)

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: MiR-195 regulates CD40 to maintain Th17/Treg balance in rats with non-alcoholic fatty liver disease.

doi: 10.1016/j.biopha.2020.109930

Figure Lengend Snippet: Fig. 1. MiR-195 can negatively regulate CD40 expression. A: Bioinformatics prediction results. B: Dual-luciferase reporter gene assay. Compared with NC-mimic, *P < 0.05. C: Expressions of miR-19 and CD40 in liver of rats in each group through quantitative reverse transcriptase PCR. D: Protein band diagram. E: Expression of CD40 protein in liver of rats in each group through western blot analysis. Compared with Normal group, *P < 0.05; compared with NC group, #P < 0.05.

Article Snippet: The proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis SDS-PAGE and transferred to polyvinylidene difluoride PVDF membrane at a constant voltage of 80 V. After being sealed for 1 h, the membrane was incubated with anti-rabbit polyclonal primary antibodies against CD40 1: 1000; ab13545; Abcam, USA, RORyt 1: 500; ab181883; Abcam, USA, Foxp3 1: 1000; ab215206; Abcam, USA, IL-17 1: 3000; ab111553; Abcam, USA, IL-10 1:1000; ab9969; Abcam, USA, TNF-α 1: 2000; ab6671; Abcam, USA, IL-23 1: 2000; ab80893; Abcam, USA, IL-6 1: 1000; ab208113; Abcam, USA, IL-8 1: 1000; ab118617; Abcam, USA, GAPDH 1: 10,000; ab181602; Abcam, USA, then was incubated with secondary antibody, goat anti-rabbit IgG at 4°C overnight.

Techniques: Expressing, Luciferase, Reporter Gene Assay, Reverse Transcription, Western Blot